Company news
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) news
Every Jazz Pharmaceuticals Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concu...
August 27, 2026
Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repur...
August 26, 2026
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
August 10, 2026
Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
August 3, 2026
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026
July 20, 2026
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
June 17, 2026
Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, ...
June 16, 2026
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
June 12, 2026
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, pota...
June 4, 2026
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera...
May 27, 2026
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
May 5, 2026
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Ca...
April 30, 2026
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab...
April 27, 2026
HealthCare Royalty Announces Royalty Monetization Agreement for Modeyso® Commercial Royalties
April 22, 2026
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
April 21, 2026
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarc...
April 21, 2026
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral...
April 9, 2026
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
April 1, 2026
American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascul...
March 24, 2026
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
March 18, 2026
Rylaze (Jazz Pharmaceuticals) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025,...
March 13, 2026
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
February 24, 2026
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
February 17, 2026
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
February 10, 2026
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
January 12, 2026
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
January 8, 2026
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including M...
January 6, 2026
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
December 17, 2025
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Re...
December 5, 2025
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally A...
December 2, 2025
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
November 18, 2025
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regi...
November 17, 2025
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regi...
November 17, 2025
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma a...
November 11, 2025
Iambic Raises Over $100 Million in an Oversubscribed Round to Advance Its Portfolio of AI-Discovered Therapeutics and Leading Platform Te...
November 10, 2025
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
November 5, 2025
Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
October 28, 2025
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
October 22, 2025
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast ...
October 21, 2025
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Sm...
October 2, 2025
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treat...
September 22, 2025
Design Therapeutics Appoints Justin Gover to Board of Directors
September 10, 2025
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-m...
September 9, 2025
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
August 21, 2025
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
August 20, 2025
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
August 20, 2025
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
August 13, 2025
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant ...
August 6, 2025
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
August 5, 2025
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
July 22, 2025